Abstract Background -Only a small proportion of patients with non-small cell lung cancer (NSCLC) attending radiotherapy centres were suitable for inclusion in a randomised trial which compared continuous hyperfractionated accelerated radiotherapy (CHART) with conventional radical radiotherapy. As this was thought to be partly due to delays in the referral of patients to clinical oncologists, a prospective study was performed to determine the interval between first report of symptoms and first radiotherapy treatment in patients with NSCLC. Methods -The time course from first symptom to treatment was determined in all patients with NSCLC attending 10 cancer centres for radiotherapy to a primary tumour in a three month period. Results -Only 5% of 484 patients were suitable for the trial of radical radiotherapy. The principal causes for exclusion were poor general condition (37%), too large a tumour (27%), and extrathoracic metastases (19%) . The median time from first symptom to diagnosis was 13 weeks, from first symptom to first treatment 19 weeks, and from diagnosis to first treatment five weeks. In a quarter of the patients these intervals were greater than 25, 33 There are a few patients who present with small early tumours who do not have surgery, either because of the site of the tumour or because the patient is medically unsuitable, or because the patient refuses surgery. In such cases high dose (radical) radiotherapy may achieve results comparable to those in resected cases.5 However, the number of patients currently treated with high dose radiotherapy is small and makes no impact upon the general problem of the management of lung cancer.
A much larger number ofpatients with locally advanced inoperable tumours show no evidence of distant spread at the time of investigation. When these patients are referred to centres in the UK the general policy is to employ low dose radiotherapy with palliative intent. In North America and in continental Europe high doses are commonly given but the value in terms of primary tumour control or cure is arguable.
In The essential requirements for inclusion in the lung cancer trial were a WHO performance status 0 or 1 and a locally advanced NSCLC unsuitable for surgery with no evidence ofmetastases outside the thorax. The area to be treated within the chest, when viewed anteriorly, was not to exceed 240 cm2 so that a radical course of radiotherapy could be given without risk of serious impairment of lung function. Entry to the study began in February 1990 and by March 1995 a total of 563 patients with NSCLC had been entered by the 13 centres participating in the study.
The rate of accrual of patients with lung cancer was slower than those with head and neck cancer where, in the same period of time, 918 patients were entered. It was reported from all the centres that most patients with NSCLC were not included because they did not satisfy the criteria for entry. A survey in Glasgow suggested that fewer than 5% of cases presenting to the cancer centre could be included; most commonly the tumours were too advanced within the chest, or the patient's general condition was too poor (Macbeth, personal communication).
Because of the view held generally in the UK that patients with locally advanced disease should only be given palliative radiotherapy, the CHART Steering Committee felt that there might be delays in referrals so that some patients who were suitable for radical radiotherapy at the time of presentation to their general practitioner no longer fulfilled the requirements for inclusion when finally seen by a clinical oncologist. Further, it was considered important that the patients included in the randomised trial be placed in the context of all those presenting to cancer centres with the same clinical condition. It was decided therefore to perform a survey of all patients with lung cancer who received any radiotherapy to the primary tumour at the cancer centres contributing to the CHART trials.
As the data were gathered at the time when the patients were being prepared for treatment it was possible to check dates with them. The date of diagnosis was, in most cases, the date when histological or cytological proof of diagnosis was available. In some of the more advanced cases, however, histological or cytological proof was not obtained and the diagnosis rested on the clinical findings. In such a case the date given was the one where the diagnosis was considered so certain that management decisions could be made.
Results
In one large centre less than 10% of the expected number of forms were completed and the data from this centre were therefore excluded from the analysis.
A total of 524 patients receiving radiotherapy to the primary tumour during the three month period of the survey were recorded in the remaining 12 centres. Of these, 40 had first undergone tumour resection and these have been excluded from further analysis leaving 484 cases (table 1) . A further 34 patients were included who had undergone thoracotomy but in whom resection was not possible. The numbers contributed by each centre varied widely reflecting both the population served and the number of patients contributed annually to the randomised trial.
Patient details are shown in A trial co-ordinator (nurse or therapy radiographer) collected the data in each centre. The dates of onset of symptoms, first attendance at a general practitioner, hospital, oncologist, and of the start of treatment were determined The hospital notes and referral letters were available to the local trial co-ordinators for the data to be extracted and, where necessary, they consulted the clinical oncologist. In addition, the dose and fractionation of the radiotherapy given was recorded and, in those excluded from the CHART trial, the principal reason for that decision. It was felt realistic only to request the month and year of onset of the first symptom whereas with the other data the day was recorded. 
Discussion
The median interval between first symptom and presentation to a general practitioner was three weeks. Many patients with lung cancer have pre-existing lung disease, often related to cigarette smoking, but it seems likely that an additional symptom such as haemoptysis, increase in severity of cough, shortness of breath, or superadded respiratory infection brought the patient to the family doctor. The median interval of four weeks from presentation to the general practitioner to first attendance at hospital appears satisfactory as it includes the delay between referral and clinic attendance. However, the time between onset of first symptom and first attendance at the general practitioner was not verified by referral to the general practitioners' notes.
The interval from first attendance at hospital to diagnosis again seems satisfactory but a greater interval appears to occur (median 3 weeks, range 1-6 weeks) between the time of the diagnosis and the patients' visit to a clinical oncologist. Perhaps in some cases this interval was affected by the commonly held view that nearly all patients with inoperable NSCLC should only receive radiotherapy for palliation of symptoms, and that a "watch" policy should be followed in those with no symptoms.
The median interval between first seeing an oncologist and attendance for first treatment was one week which seemed satisfactory, especially considering the heavy workload of many of the UK centres taking part in the CHART trial. As most of these patients were selected immediately for palliative rather than curative radiotherapy, the interval between first attendance and the start of treatment was not extended because of further investigation. The median interval between first attendance and the start of radical treatment was longer.
However, concentrating on median values diverts attention from the longer time intervals experienced by many patients at the various stages leading to treatment. A quarter of the patients experienced a delay of more than nine weeks between first attending their general practitioner and attending hospital. Also, more than a quarter of the patients did not see an oncologist until more than eight weeks after seeing their first hospital specialist.
The time observed for lung tumours to double their volume ranges from four to 56 weeks with a median of 17 weeks.89 With the faster growing tumours and the longer intervals in the process from initial referral to diagnosis and attendance for radiotherapy, a doubling of the bulk of the primary tumour may have occurred together with local and distant spread.
It is of interest that the Standing Medical Advisory Committee's Working Group in its report on the management of lung cancer recommends that, for patients where surgical resection is planned, no more than 6-8 weeks should elapse between the patient's first presentation to the general practitioner and the operation.' A similar recommendation ought to be appropriate for patients accepted for another type of radical treatment.
In general the number of attendances for radiotherapy in the UK centres was small. Nearly half the patients were treated in three or fewer fractions. This demonstrates the current practice for palliation in The interim report of the CHART randomised trials has shown significantly improved survival of the CHART treated cases compared with those treated by conventional radiotherapy7 with an improvement in the two year overall survival from 20% to 30% (p = 0.006). This result encourages the use of radiotherapy and the CHART regime in advanced but apparently localised NSCLC in patients with good performance status. Of the large number of patients who presently receive palliative radiotherapy in the UK some might be suitable for more radical treatment if referred at an earlier stage in their illness. The detailed reasons for the long delays experienced by some of these patients between first symptom and start of treatment could usefully be the subject of prospective audits.
